An Exploration of Some Predictors of Quality of Life-Related to the Innate Immune System, Inflammation, and Disease Activity in Patients with Behcet's Syndrome: An Analytical Cross-sectional Study.

BACKGROUND: Behçet's disease (BD) has a growing prevalence in Silk Road countries. The aim of our cross-sectional study was to explore the clinical and molecular predictors of quality of life in BD patients. MATERIALS AND METHODS: One hundred and fifty consecutive Iranian BD patients with an age range between 20-50 years were included. The Leeds Behçet's disease quality of life (BDQoL) in Persian form was fulfilled to evaluate the quality of life. Anthropometric measurements were carried out using the calibrated scales. Iranian Behcet's Disease Dynamic Activity Measure (IBDDAM), Behcet's disease current activity form (BDCAF), and Total Inflammatory Activity Index (TIAI) were used to assess BD activity. mRNA expression of toll-like receptors 2 and 4 (TLR2 and TLR4) and tumor-necrosis-factor-alpha (TNF-α) levels in serum were measured by real-time polymerase chain reaction (PCR) and ELISA, respectively. Multiple linear backward regression at P = 0.1 was used to study the potential predictors of quality of life. RESULTS: TLR2 and BDCAF were shown to be the most important predictors of quality of life in BD patients by 22%. There were positive associations between them (ß = 0.326, p = 0.013 for BDCAF; ß = 0.366, p = 0.006 for TLR2) and BDQoL value. CONCLUSION: Higher TLR2 expression as a key protein in recognizing pathogens by innate immunity and BDCAF value as a comprehensive BD assessing scale contribute to poor quality of life among BD patients. Emphasizing therapeutically, approaches associated with lower TLR2 expression and BDCAF value can be considered in future studies.

Efficacy of vitamin D supplementation as an adjunct therapy for improving inflammatory and oxidative stress biomarkers: An umbrella meta-analysis.

BACKGROUND: Vitamin D supplementation has attracted a lot of attention as a potential modulator of inflammation and oxidative stress, while some studies have reported controversial findings. In this regard, the purpose of this study was to summarize existing systematic reviews and meta-analyses of clinical trials that determined the effects of supplementation with vitamin D on inflammatory and oxidative biomarkers. METHODS: The following international databases were systematically searched till March 20th, 2022: PubMed, Scopus, Embase, Web of Science, and Google Scholar. A random-effects model was applied to evaluate the effects of vitamin D on inflammatory and oxidative stress biomarkers. RESULTS: Overall, 23 meta-analyses were qualified in this umbrella meta-analysis. Our findings revealed that the vitamin D supplementation significantly reduced serum C-reactive protein (CRP) (ES = -0.42; 95% CI: -0.55, -0.29, p < 0.001), tumor necrosis factor-α (TNF-α) (ES = -0.27; 95% CI: -0.42, -0.12; p < 0.001), and malondialdehyde (MDA) concentrations (ES = -0.37; 95% CI: -0.48, -0.25, p < 0.001). However, no significant changes were illustrated regarding interleukin-6 (IL-6) (ES = -0.35, 95% CI: -0.80, 0.10; p = 0.125), total antioxidant capacity (TAC) (ES = 0.68; 95% CI: -0.31, 1.66, p = 0.179), and glutathione (GSH) activity (ES = 0.08; 95% CI: -0.44, 0.60, p = 0.757). CONCLUSION: The present umbrella meta-analysis indicated that supplementation of vitamin D in adults can improve CRP, TNF-α, and MDA levels under various health conditions. Vitamin D could be considered an adjuvant therapy for relieving inflammation and oxidative stress.

Anti-hypertensive Effects of Artichoke Supplementation in Adults: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials.

Despite controversies, no earlier study has systematically summarized findings from earlier studies on the effect of artichoke supplementation on blood pressure. Therefore, current systematic review and meta-analysis was done on the effect of artichoke supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adults. Five databases were searched from inception to January 2022 using relevant keywords. All randomized clinical trials investigating the impact of oral artichoke supplementation on any of the blood pressure parameters including SBP or/and DBP were included. Out of 1,507 citations, 7 trials that enrolled 472 subjects were included. Artichoke supplementation resulted in significant reduction in SBP (weighted mean difference [WMD], -2.01 mmHg; 95% confidence interval [CI], -3.78, -0.24; p = 0.026) and DBP (WMD, -1.45 mmHg; 95% CI, -2.81, -0.08; p = 0.038). Greater effects on SBP were detected in trials using ≤ 500 mg artichoke, lasted > 8 weeks, participants aged < 50 years' old and sample size ≤ 70. There was also a similar impact of artichoke on DBP. However, significant non-linear associations were found between artichoke supplementation dosage and study duration with both SBP (for dosage: pnon-linearity = 0.002, for duration: pnon-linearity = 0.016) and DBP (for dosage: pnon-linearity = 0.005, for duration: pnon-linearity = 0.003). We found a significant reduction in both SBP and DBP following artichoke supplementation in adults. It could be proposed as a hypotensive supplement in hypertension management.